Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133684) titled 'Initial dual-drug combination therapy with finerenone, dapagliflozin, or semaglutide in patients with type 2 Diabetes related chronic kidney disease' on Sept. 30.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Anhui Medical University
Condition:
Type 2 diabetes mellitus with diabetic kidney disease
Intervention:
Group C:Combination therapy with dapagliflozin and semaglutide
Group A:Combination therapy with finerenone and dapagliflozin
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: Group...